Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)

2019-10-23 13:11:51 | BioPortfolio


The purpose of this non-interventional, prospective study is to evaluate the real world long-term effectiveness of lanadelumab in participants with type 1 or type 2 HAE.

Study Design


Hereditary Angioedema (HAE)


Medical University of Vienna


Not yet recruiting



Results (where available)

View Results


Published on BioPortfolio: 2019-10-23T13:11:51-0400

Clinical Trials [242 Associated Clinical Trials listed on BioPortfolio]

Epidemiological Analysis for Hereditary Angioedema Disease (EHA Study)

To explore the feasibility of a new Dried Blood Spot (DBS) filtercard-based screening algorithm and thereby analyzing the prevalence of the Hereditary Angioedema in patients with unclear r...

The Role of the Coagulation Pathways in Recurrent Angioedema

Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema. This study aim to compare groups w...

Involvement of Monocytic B1 and B2 Receptors in Inflammation and Chronic Vascular Disease in Patients With Hereditary Bradykinetic Angioedema

The objective is to compare the gene expression of B1 and / or B2 monocyte receptors between patients with hereditary bradykinetic angioedema and control subjects.

Cinryze for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

The objectives of the study are to: 1. Evaluate the dose response and the pharmacokinetics (PK)/pharmacodynamics (PD) of intravenous (IV) administration of Cinryze for the treatmen...

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Hereditary angioedema ("HAE") is a genetic disorder characterized by sudden recurrent attacks of local swelling (angioedema). These attacks are often painful and disabling, and, in some ca...

PubMed Articles [416 Associated PubMed Articles listed on BioPortfolio]

Advances in Drug Allergy, Urticaria, Angioedema and Anaphylaxis in 2018.

Many notable advances in drug allergy, urticaria, angioedema and anaphylaxis were reported in 2018. Broad spectrum antibiotic use and consequently antibiotic resistance is widespread, and algorithms t...

Hereditary Angioedema: looking for bradykinin production and triggers of vascular permeability.

Since the Osler's identification of the inherited nature of Hereditary Angioedema, a huge array of information was collected on pathogenetic mechanisms of the disease. Over the last years, information...

Hereditary Angioedema: Insights into inflammation and allergy.

Hereditary Angioedema (HAE) is a rare autosomal recessive bradykinin (BK)-mediated disease characterized by local episodes of non-pitting swelling. Initially considered a complement-mediated disease, ...

Clinical Features and Outcomes Associated with Angioedema in the Emergency Department.

Angioedema represents self-limited, localized swelling of submucosal or subcutaneous tissues. While the underlying etiology may be undeterminable in the emergent setting, nonhistaminergic and histamin...

Recombinant Human C1 Esterase Inhibitor as Short-Term Prophylaxis in Patients With Hereditary Angioedema.

Medical and Biotech [MESH] Definitions

Forms of hereditary angioedema that occur due to mutations in the gene for COMPLEMENT C1 INHIBITOR PROTEIN. Type I hereditary angioedema is associated with reduced serum levels of complement C1 inhibitor protein. Type II hereditary angioedema is associated with the production of a non-functional complement C1 inhibitor protein.

A form of hereditary angioedema that occurs in women and is precipitated or worsened by high ESTROGEN levels. It is associated with mutations in the gene for FACTOR XII that result in its increased activity.

Swelling involving the deep DERMIS, subcutaneous, or submucosal tissues, representing localized EDEMA. Angioedema often occurs in the face, lips, tongue, and larynx.

An endogenous 105-kDa plasma glycoprotein produced primarily by the LIVER and MONOCYTES. It inhibits a broad spectrum of proteases, including the COMPLEMENT C1R and the COMPLEMENT C1S proteases of the CLASSICAL COMPLEMENT PATHWAY, and the MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES. C1-INH-deficient individuals suffer from HEREDITARY ANGIOEDEMA TYPES I AND II.

Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III.

More From BioPortfolio on "Study to Evaluate the Real-World Long-Term Effectiveness of Lanadelumab in Participants With Hereditary Angioedema (HAE)"

Quick Search

Searches Linking to this Trial